LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 12

Search options

  1. Article ; Online: Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma.

    Othman, Tamer / Lowsky, Robert / Richman, Carol / Hoeg, Rasmus / Abedi, Mehrdad / Tuscano, Joseph

    Bone marrow transplantation

    2023  Volume 58, Issue 10, Page(s) 1143–1145

    MeSH term(s) Humans ; Lymphoma, Non-Hodgkin/therapy ; Lymphoma, Non-Hodgkin/pathology ; Yttrium Radioisotopes/therapeutic use ; Hematopoietic Stem Cell Transplantation ; Radioimmunotherapy
    Chemical Substances Yttrium-90 (1K8M7UR6O1) ; ibritumomab tiuxetan (4Q52C550XK) ; Yttrium Radioisotopes
    Language English
    Publishing date 2023-06-30
    Publishing country England
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 632854-4
    ISSN 1476-5365 ; 0268-3369 ; 0951-3078
    ISSN (online) 1476-5365
    ISSN 0268-3369 ; 0951-3078
    DOI 10.1038/s41409-023-02025-0
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Safety and tolerability of lenalidomide maintenance in post-transplant acute myeloid leukemia and high-risk myelodysplastic syndrome.

    Pham, Brian / Hoeg, Rasmus / Krishnan, Rajeev / Richman, Carol / Tuscano, Joseph / Abedi, Mehrdad

    Bone marrow transplantation

    2021  Volume 56, Issue 12, Page(s) 2975–2980

    Abstract: Relapse after allogeneic stem cell transplant in unfavorable-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) portends a poor prognosis. We conducted a single-center phase I dose-escalation study with lenalidomide ... ...

    Abstract Relapse after allogeneic stem cell transplant in unfavorable-risk acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) portends a poor prognosis. We conducted a single-center phase I dose-escalation study with lenalidomide maintenance in high-risk MDS and AML patients after allogeneic transplantation. Sixteen patients enrolled in a "3 + 3" study design starting at lenalidomide 5 mg daily, increasing in increments of 5 mg up to 15 mg. Lenalidomide was given for 21 days of a 28-day cycle for a total of six cycles. Most common dose-limiting toxicities were lymphopenia, diarrhea, nausea, and neutropenia. Two patients had acute graft-versus-host disease (GVHD), and five patients developed chronic GVHD. The maximum tolerated dose was 10 mg, after dose-limiting toxicities were seen in the 15 mg group. Two dose-limiting toxicities were seen from development of acute GVHD and grade III diarrhea. Limitations of the study include time to initiation at 6 months post transplant, as many high-risk patients will have relapsed within this time frame before starting maintenance lenalidomide. Overall, lenalidomide was well tolerated with minimal GVHD and low rates of relapse rates, warranting further study.
    MeSH term(s) Graft vs Host Disease/drug therapy ; Hematopoietic Stem Cell Transplantation ; Humans ; Lenalidomide/adverse effects ; Leukemia, Myeloid, Acute/drug therapy ; Myelodysplastic Syndromes/drug therapy ; Transplantation, Homologous
    Chemical Substances Lenalidomide (F0P408N6V4)
    Language English
    Publishing date 2021-09-01
    Publishing country England
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 632854-4
    ISSN 1476-5365 ; 0268-3369 ; 0951-3078
    ISSN (online) 1476-5365
    ISSN 0268-3369 ; 0951-3078
    DOI 10.1038/s41409-021-01444-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2168: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies.

    Hoeg, Rasmus T / Davis, Julian / Jonas, Brian A / Tuscano, Joseph / Rosenberg, Aaron / Abedi, Mehrdad

    Clinical lymphoma, myeloma & leukemia

    2020  Volume 20, Issue 7, Page(s) 453–458

    Abstract: Introduction: Everolimus and bendamustine both have single-agent activity against lymphoid hematologic malignancies. We examined this combination in a group of heavily pretreated patients with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and ... ...

    Abstract Introduction: Everolimus and bendamustine both have single-agent activity against lymphoid hematologic malignancies. We examined this combination in a group of heavily pretreated patients with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and multiple myeloma (MM).
    Patients and methods: In this phase I trial, 18 patients (8 with NHL, 6 with MM, and 4 with HL) were treated with bendamustine 90 mg/m
    Results: Adverse events were generally mild and mostly hematologic in nature. The most frequent grade 3/4 adverse events were lymphopenia (61%), thrombocytopenia (22%), leukopenia (22%), neutropenia (17%), and fatigue (17%). Overall response rate varied by malignancy: diffuse large B-cell lymphoma, 20% (1 of 5 patients); HL (2 of 4 patients), 50%; MM, 80% (4 of 5 patients); and indolent lymphomas, 100% (3 of 3 patients). The maximum tolerated dose of everolimus was determined to be 7.5 mg daily.
    Conclusion: The combination of everolimus and bendamustine appeared to be well-tolerated and relatively efficacious.
    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Bendamustine Hydrochloride/pharmacology ; Bendamustine Hydrochloride/therapeutic use ; Everolimus/pharmacology ; Everolimus/therapeutic use ; Female ; Hematologic Neoplasms/drug therapy ; Humans ; Male ; Middle Aged ; Prospective Studies ; Young Adult
    Chemical Substances Antineoplastic Agents ; Bendamustine Hydrochloride (981Y8SX18M) ; Everolimus (9HW64Q8G6G)
    Language English
    Publishing date 2020-02-20
    Publishing country United States
    Document type Clinical Trial, Phase I ; Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2020.02.006
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center.

    Tenold, Matthew E / Moskoff, Benjamin N / Benjamin, David J / Hoeg, Rasmus T / Rosenberg, Aaron S / Abedi, Mehrdad / Tuscano, Joseph M / Jonas, Brian A

    Frontiers in oncology

    2021  Volume 11, Page(s) 649209

    Abstract: Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using ... ...

    Abstract Relapsed/refractory acute myeloid leukemia (AML) is a devastating disease with a poor prognosis and represents a major unmet medical need. We report on a real-world academic center experience of treating 25 patients with relapsed/refractory AML using venetoclax in combination with decitabine or azacitidine, which is not otherwise widely evaluated in the current literature. Our patients come from a large, socioeconomically and geographically diverse area including the majority of Northern California. Most had ELN Adverse Risk (52%) or Intermediate Risk (44%) AML, and most had an ECOG Performance Status of 1 (64%). Over half (52%) had prior hypomethylating agent exposure, and 40% had Secondary AML. We observed an overall response rate of 52%, with eight patients (32%) achieving composite complete remission. Median overall survival was 5.5 months, and for patients achieving composite complete remission this was 21.6 months. One-year estimated overall survival was 38%. Three patients were able to proceed directly to stem cell transplant for consolidation, and all three were alive at last follow-up, ranging 13.8-24.0 months. We found venetoclax in combination with hypomethylating agents to be well tolerated and potentially efficacious in securing long-term remissions for patients with relapsed/refractory AML.
    Language English
    Publishing date 2021-03-11
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2021.649209
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.

    Tenold, Matthew E / Moskoff, Benjamin N / Krishnan, Rajeev / Rosenberg, Aaron S / Hoeg, Rasmus T / Abedi, Mehrdad / Tuscano, Joseph M / Jonas, Brian A

    Clinical lymphoma, myeloma & leukemia

    2021  Volume 21, Issue 7, Page(s) e611–e618

    Abstract: Background: FLAG ± Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin), is a salvage chemotherapy regimen for relapsed or refractory (R/R) acute myeloid leukemia (AML), with complete remission (CR) rates historically ... ...

    Abstract Background: FLAG ± Ida (fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin), is a salvage chemotherapy regimen for relapsed or refractory (R/R) acute myeloid leukemia (AML), with complete remission (CR) rates historically ranging from 52% to 63%. We review the outcomes for patients with R/R AML treated with FLAG ± Ida at the University of California Davis Comprehensive Cancer Center.
    Patients and methods: Adult patients (≥ 18 years) with R/R AML who received FLAG or FLAG + Ida from January 1, 2012 to October 31, 2016 were identified via chart review. Outcomes evaluated were CR, CR with incomplete hematologic recovery (CRi), overall response rate, overall survival (OS), relapse-free survival, and adverse events.
    Results: Forty-two patients were included. The median age was 52 years (range, 23-73 years), and 57% were male. Sixteen (38.1%) patients had relapsed disease, and 26 (61.9%) had refractory disease. Most (n = 35; 83.3%) patients had European LeukemiaNet intermediate-risk AML. Responses were CR in 20 (47.6%) and CRi in 6 (14.3%). The median OS was 10 months (range, 0.8-51 months), and the median relapse-free survival was 12 months (range, 1-51 months) for responders. The median OS for patients who achieved CR was not reached, and the estimated 48-month survival rate was 56%. The median OS after CRi or no response was 3.47 and 2.17 months, respectively. The median OS was not significantly different when censored for stem cell transplant following chemotherapy, nor with use/deferral of idarubicin. The most common adverse effects were pancytopenia and infection.
    Conclusion: Patient outcomes after treatment with FLAG ± Ida for R/R AML remain similar to prior reports, confirming its role as a salvage regimen for these patients.
    MeSH term(s) Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cancer Care Facilities/statistics & numerical data ; Cytarabine/administration & dosage ; Cytarabine/adverse effects ; Disease-Free Survival ; Drug Resistance, Neoplasm ; Female ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Granulocyte Colony-Stimulating Factor/adverse effects ; Hematopoietic Stem Cell Transplantation/statistics & numerical data ; Humans ; Idarubicin/administration & dosage ; Idarubicin/adverse effects ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/pathology ; Leukemia, Myeloid, Acute/therapy ; Male ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/therapy ; Pancytopenia/chemically induced ; Pancytopenia/epidemiology ; Retrospective Studies ; Salvage Therapy/methods ; Salvage Therapy/statistics & numerical data ; Survival Rate ; Vidarabine/administration & dosage ; Vidarabine/adverse effects ; Vidarabine/analogs & derivatives ; Young Adult
    Chemical Substances Cytarabine (04079A1RDZ) ; Granulocyte Colony-Stimulating Factor (143011-72-7) ; Vidarabine (FA2DM6879K) ; Idarubicin (ZRP63D75JW)
    Language English
    Publishing date 2021-03-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2021.02.007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Phase I study of escalating doses of carfilzomib with HyperCVAD in patients with newly diagnosed acute lymphoblastic leukemia.

    Jonas, Brian A / Fisch, Samantha C / Rosenberg, Aaron S / Hoeg, Rasmus T / Tuscano, Joseph M / Abedi, Mehrdad

    American journal of hematology

    2021  Volume 96, Issue 4, Page(s) E114–E117

    MeSH term(s) Adult ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Doxorubicin/administration & dosage ; Doxorubicin/adverse effects ; Female ; Hematologic Diseases/chemically induced ; Humans ; Hypocalcemia/chemically induced ; Hyponatremia/chemically induced ; Male ; Middle Aged ; Neoplasm, Residual ; Oligopeptides/administration & dosage ; Oligopeptides/adverse effects ; Peripheral Nervous System Diseases/chemically induced ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Rituximab/administration & dosage ; Treatment Outcome ; Vincristine/administration & dosage ; Vincristine/adverse effects ; Young Adult
    Chemical Substances Oligopeptides ; Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; carfilzomib (72X6E3J5AR) ; Dexamethasone (7S5I7G3JQL) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P)
    Language English
    Publishing date 2021-02-26
    Publishing country United States
    Document type Clinical Trial, Phase I ; Letter ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 196767-8
    ISSN 1096-8652 ; 0361-8609
    ISSN (online) 1096-8652
    ISSN 0361-8609
    DOI 10.1002/ajh.26105
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1251: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Clinical experience with frontline Hyper-CVAD-based regimens, including Hyper-CVAD plus ponatinib, in patients with acute lymphoblastic leukemia treated at a comprehensive cancer center.

    Othman, Tamer / Moskoff, Benjamin N / Ho, Gwendolyn / Tenold, Matthew E / Azenkot, Tali / Krackeler, Margaret L / Fisch, Samantha C / Potter, Laura A / Kaesberg, Paul R / Welborn, Jeanna L / Wun, Ted / Esteghamat, Naseem S / Hoeg, Rasmus T / Rosenberg, Aaron S / Abedi, Mehrdad / Tuscano, Joseph M / Jonas, Brian A

    Leukemia research

    2022  Volume 119, Page(s) 106885

    Abstract: Background: Hyper-CVAD is an established regimen for adult ALL that was developed at the MD Anderson Cancer Center (MDACC). However, results can vary across different institutions given the heterogeneity of patient populations and institutional ... ...

    Abstract Background: Hyper-CVAD is an established regimen for adult ALL that was developed at the MD Anderson Cancer Center (MDACC). However, results can vary across different institutions given the heterogeneity of patient populations and institutional practices. Moreover, while a MDACC study demonstrated that the combination of ponatinib plus hyper-CVAD produced remarkable activity in untreated Ph+ ALL, it remains to be externally validated. We sought to validate those findings in previously untreated adult patients with Ph+ ALL.
    Methods: This was a retrospective study analyzing the outcomes of previously untreated adult ALL patients treated with hyper-CVAD, with a focus on Ph+ ALL patients treated with ponatinib plus hyper-CVAD.
    Results: 82 patients were included. The median age was 51 years. The median follow-up was 2.62 years. The 5-year overall survival (OS) and event-free survival (EFS) were 39.5 % and 28.2 %, respectively. For Ph+ ALL patients (n = 13) receiving ponatinib plus hyper-CVAD, 3-year OS and EFS were both 92.3 %. Univariate analysis showed a high WBC and poor-risk cytogenetics to be associated with inferior outcomes, while CD20 + predicted favorable outcomes in B-ALL patients. On multivariate analysis, CD20 + retained significance for Philadelphia-negative (Ph-) ALL. For Ph+ ALL, ponatinib was associated with better OS and EFS on univariate and multivariate analysis.
    Conclusion: Our data supports the use of ponatinib plus hyper-CVAD as a standard of care regimen for Ph+ ALL. Our outcomes for Ph-ALL and T-cell ALL (T-ALL) show that advances are still needed in the frontline setting, and clinical trial enrollment is recommended.
    MeSH term(s) Adult ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/therapeutic use ; Dexamethasone/therapeutic use ; Doxorubicin/therapeutic use ; Humans ; Imidazoles ; Middle Aged ; Philadelphia Chromosome ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Pyridazines ; Retrospective Studies ; Vincristine/therapeutic use
    Chemical Substances Imidazoles ; Pyridazines ; ponatinib (4340891KFS) ; Vincristine (5J49Q6B70F) ; Dexamethasone (7S5I7G3JQL) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P)
    Language English
    Publishing date 2022-06-08
    Publishing country England
    Document type Journal Article
    ZDB-ID 752396-8
    ISSN 1873-5835 ; 0145-2126
    ISSN (online) 1873-5835
    ISSN 0145-2126
    DOI 10.1016/j.leukres.2022.106885
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1321: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas.

    Othman, Tamer / Moskoff, Benjamin N / Esteghamat, Naseem / Hoeg, Rasmus T / Rosenberg, Aaron S / Jonas, Brian A / Abedi, Mehrdad / Richman, Carol / Tuscano, Joseph M

    Leukemia & lymphoma

    2021  Volume 63, Issue 1, Page(s) 231–234

    MeSH term(s) Antilymphocyte Serum ; Graft vs Host Disease ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma/diagnosis ; Lymphoma/therapy ; Transplantation Conditioning
    Chemical Substances Antilymphocyte Serum
    Language English
    Publishing date 2021-09-06
    Publishing country United States
    Document type Letter
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2021.1975190
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2997: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Management of neutropenic fever during a transition from traditional hematology/oncology service to hospitalist care.

    Raghavendra, Meghana / Hoeg, Rasmus T / Bottner, Wayne A / Agger, William A

    WMJ : official publication of the State Medical Society of Wisconsin

    2014  Volume 113, Issue 2, Page(s) 53–58

    Abstract: Objectives: Increasingly, hospitalists across the United States provide primary inpatient care for almost all subspecialty patients, including hematology and medical oncology. Febrile neutropenia (FN) is a serious condition often seen as a complication ... ...

    Abstract Objectives: Increasingly, hospitalists across the United States provide primary inpatient care for almost all subspecialty patients, including hematology and medical oncology. Febrile neutropenia (FN) is a serious condition often seen as a complication of cytotoxic chemotherapy or in patients with underlying bone marrow defects. The purpose of this study was to document the change of inpatient management of a common admission diagnosis during a transition of providers from hematologists/oncologists to the use of hospitalists in a tertiary care medical center, and to compare the appropriateness of treatment and outcomes over a period of 5.5 years of this transition.
    Methods: The medical records of all patients with neutropenia at a community-based teaching hospital during a period of conversion from hematologist/oncologist to hospitalist coverage were retrospectively reviewed. Patients with fever and absolute neutrophil counts of less than 500/ microL (.5 x 10(9)/L) on admission were included. Study cases were divided into 3 groups by admission date, roughly demarcating the nascent hospitalist era, the era of transition to hospitalist, and the mature hospitalist era. Management of FN during these eras was compared.
    Results: Three hundred ninety-nine inpatients were identified as neutropenic. Of these, 184 did not meet case-inclusion criteria. The remaining 215 cases were included in the study. The internal medicine hospitalist service admitted less than 10% of this population in 2003, but by 2007-2008 it admitted over 90%. The use of 4th-generation cephalosporins and carbapenems increased over time (P = .027), and the infectious disease service was consulted more frequently over time (P = .007). Outcomes varied due to changes in underlying disease states, use of hospice services, and changes in the types of patients hospitalized with FN. Morbidity decreased due to the change in the type and nonantibiotic therapy of cases, but inappropriate antimicrobial treatment was unusual, and septic morbidity or mortality related to inappropriate therapy was too rare to compare through these eras.
    Conclusion: Over the 3 eras compared, care of most neutropenic fever patients was transferred from specialists to hospitalists. Care became more uniform, guideline based, and used more infectious disease consultation, and mortality decreased. Complex changes in the types and treatments of cancer, neutropenia therapy, and in the types of patients hospitalized with FN prevent any conclusion of added value for this change in the type of primary provider management.
    MeSH term(s) Aged ; Anti-Bacterial Agents/therapeutic use ; Febrile Neutropenia/drug therapy ; Female ; Hematology/organization & administration ; Hospitalists ; Hospitals, Teaching ; Humans ; Male ; Medical Oncology/organization & administration ; Practice Patterns, Physicians'/statistics & numerical data ; Retrospective Studies ; Treatment Outcome ; Wisconsin
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2014-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 441051-8
    ISSN 1098-1861 ; 0043-6542
    ISSN 1098-1861 ; 0043-6542
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 225: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022.

    Saad, Ayman / Loren, Alison / Bolaños-Meade, Javier / Chen, George / Couriel, Daniel / Di Stasi, Antonio / El-Jawahri, Areej / Elmariah, Hany / Farag, Sherif / Gundabolu, Krishna / Gutman, Jonathan / Ho, Vincent / Hoeg, Rasmus / Horwitz, Mitchell / Hsu, Joe / Kassim, Adetola / Kharfan Dabaja, Mohamed / Magenau, John / Martin, Thomas /
    Mielcarek, Marco / Moreira, Jonathan / Nakamura, Ryotaro / Nieto, Yago / Ninos, Cameron / Oliai, Caspian / Patel, Seema / Randolph, Brion / Schroeder, Mark / Tzachanis, Dimitrios / Varshavsky-Yanovsky, Asya Nina / Vusirikala, Madhuri / Algieri, Frankie / Pluchino, Lenora A

    Journal of the National Comprehensive Cancer Network : JNCCN

    2023  Volume 21, Issue 2, Page(s) 108–115

    Abstract: The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative ... ...

    Abstract The NCCN Guidelines for Hematopoietic Cell Transplantation (HCT) provide an evidence- and consensus-based approach for the use of autologous and allogeneic HCT in the management of malignant diseases in adult patients. HCT is a potentially curative treatment option for patients with certain types of malignancies; however, recurrent malignancy and transplant-related complications often limit the long-term survival of HCT recipients. The purpose of these guidelines is to provide guidance regarding aspects of HCT, including pretransplant recipient evaluation, hematopoietic cell mobilization, and treatment of graft-versus-host disease-a major complication of allogeneic HCT-to enable the patient and clinician to assess management options in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for HCT, including the incorporation of a newly developed section on the Principles of Conditioning for HCT.
    MeSH term(s) Adult ; Humans ; Transplantation, Homologous ; Neoplasm Recurrence, Local ; Hematopoietic Stem Cell Transplantation/adverse effects ; Graft vs Host Disease/diagnosis ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Transplantation Conditioning/adverse effects
    Language English
    Publishing date 2023-02-13
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2250759-0
    ISSN 1540-1413 ; 1540-1405
    ISSN (online) 1540-1413
    ISSN 1540-1405
    DOI 10.6004/jnccn.2023.0007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6365: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top